{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T01:00:27Z","timestamp":1781053227311,"version":"3.54.1"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015756","name":"Cilag","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015756","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.leukres.2026.108230","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T17:18:41Z","timestamp":1776100721000},"page":"108230","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["An Italian Delphi consensus on the current and future burden and clinical management of lenalidomide-refractory multiple myeloma"],"prefix":"10.1016","volume":"166","author":[{"given":"Paolo","family":"Corradini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3277-6594","authenticated-orcid":false,"given":"Pellegrino","family":"Musto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlotta","family":"Galeone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Mariani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Resci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Cavo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2026.108230_bib1","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","article-title":"Multiple myeloma","volume":"397","author":"van de Donk","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.leukres.2026.108230_bib2","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1001\/jamaoncol.2018.2128","article-title":"Global Burden of Multiple Myeloma: A Systematic Analysis for the Global Burden of Disease Study 2016","volume":"4","author":"Cowan","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.leukres.2026.108230_bib3","series-title":"Cancer Today","year":"2022"},{"key":"10.1016\/j.leukres.2026.108230_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-020-00359-2","article-title":"Multiple myeloma current treatment algorithms","volume":"10","author":"Rajkumar","year":"2020","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.leukres.2026.108230_bib5","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/ajh.25791","article-title":"Multiple myeloma: 2020 update on diagnosis, risk-stratification and management","volume":"95","author":"Rajkumar","year":"2020","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2026.108230_bib6","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2026.108230_bib7","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1177\/2040620718775629","article-title":"Update on the role of lenalidomide in patients with multiple myeloma","volume":"9","author":"Holstein","year":"2018","journal-title":"Ther. Adv. Hematol."},{"key":"10.1016\/j.leukres.2026.108230_bib8","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells","volume":"343","author":"Kr\u00f6nke","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.leukres.2026.108230_bib9","article-title":"Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis","volume":"5","author":"Dimopoulos","year":"2021","journal-title":"Treat. Follow-Up. Hemasphere"},{"key":"10.1016\/j.leukres.2026.108230_bib10","doi-asserted-by":"crossref","first-page":"e164","DOI":"10.1016\/j.clml.2022.12.007","article-title":"Generic Lenalidomide Rivelime Versus Brand-name Revlimid(R) in the Treatment of Relapsed\/Refractory Multiple Myeloma: A Retrospective Single-center Experience on Efficacy, Safety and Survival Outcome","volume":"23","author":"Beksac","year":"2023","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.leukres.2026.108230_bib11","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1016\/S1470-2045(20)30756-7","article-title":"Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group","volume":"22","author":"Moreau","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.leukres.2026.108230_bib12","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15010155","article-title":"How to Manage Patients with Lenalidomide-Refractory Multiple Myeloma","volume":"15","author":"de Arriba de la Fuente","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.leukres.2026.108230_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.703233","article-title":"Defining Unmet Need Following Lenalidomide Refractoriness: Real-World Evidence of Outcomes in Patients With Multiple Myeloma","volume":"11","author":"Lecat","year":"2021","journal-title":"Front Oncol."},{"key":"10.1016\/j.leukres.2026.108230_bib14","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/bjh.18658","article-title":"Real-world assessment of treatment patterns and outcomes in patients with relapsed-refractory multiple myeloma in an Italian haematological tertiary care centre","volume":"201","author":"Mor\u00e8","year":"2023","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2026.108230_bib15","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1111\/bjh.19627","article-title":"Multiple myeloma refractory to lenalidomide: A systematic literature review of trials and real-world evidence","volume":"205","author":"Hartley-Brown","year":"2024","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2026.108230_bib16","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.2217\/fon-2023-0021","article-title":"Real-world treatment patterns, healthcare resource use and disease burden in patients with multiple myeloma in Europe","volume":"19","author":"Martinez-Lopez","year":"2023","journal-title":"Future Oncol."},{"key":"10.1016\/j.leukres.2026.108230_bib17","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1182\/blood.2023022499","article-title":"BCMA- or GPRC5D-targeting bispecific antibodies in multiple myeloma: efficacy, safety, and resistance mechanisms","volume":"143","author":"Lee","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2026.108230_bib18","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41571-020-0427-6","article-title":"CAR T cell therapies for patients with multiple myeloma","volume":"18","author":"Mikkilineni","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.leukres.2026.108230_bib19","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_433516","article-title":"Bispecific Antibody Use in Patients With Lymphoma and Multiple Myeloma","volume":"44","author":"Braun","year":"2024","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"10.1016\/j.leukres.2026.108230_bib20","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1159\/000538072","article-title":"Epidemiology, Characteristics of Disease, and Unmet Needs of Patients with Generalized Pustular Psoriasis: A Large Italian Delphi Consensus","volume":"240","author":"Prignano","year":"2024","journal-title":"Dermatology"},{"key":"10.1016\/j.leukres.2026.108230_bib21","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s11739-023-03238-3","article-title":"Acid sphingomyelinase deficiency (ASMD): addressing knowledge gaps in unmet needs and patient journey in Italy-a Delphi consensus","volume":"18","author":"Scarpa","year":"2023","journal-title":"Intern Emerg. Med"},{"key":"10.1016\/j.leukres.2026.108230_bib22","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2013.12.002","article-title":"Defining consensus: a systematic review recommends methodologic criteria for reporting of Delphi studies","volume":"67","author":"Diamond","year":"2014","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.leukres.2026.108230_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1004326","article-title":"ACCORD (ACcurate COnsensus Reporting Document): A reporting guideline for consensus methods in biomedicine developed via a modified Delphi","volume":"21","author":"Gattrell","year":"2024","journal-title":"PLoS Med"},{"key":"10.1016\/j.leukres.2026.108230_bib24","doi-asserted-by":"crossref","first-page":"116","DOI":"10.5662\/wjm.v11.i4.116","article-title":"Delphi methodology in healthcare research: How to decide its appropriateness","volume":"11","author":"Nasa","year":"2021","journal-title":"World J. Method."},{"key":"10.1016\/j.leukres.2026.108230_bib25","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa2405090","article-title":"Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma","volume":"391","author":"Hungria","year":"2024","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.leukres.2026.108230_bib26","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa2403407","article-title":"Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma","volume":"391","author":"Dimopoulos","year":"2024","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.leukres.2026.108230_bib27","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3389\/fpubh.2020.00457","article-title":"Delphi Technique in Health Sciences: A Map","volume":"8","author":"Niederberger","year":"2020","journal-title":"Front Public Health"},{"key":"10.1016\/j.leukres.2026.108230_bib28","doi-asserted-by":"crossref","first-page":"246","DOI":"10.4172\/2167-1168.1000246","article-title":"Utilizing the Delphi survey approach: A review","volume":"4","author":"Shariff","year":"2015","journal-title":"J. Nurs. Care"},{"key":"10.1016\/j.leukres.2026.108230_bib29","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13023-018-0785-7","article-title":"Consensus clinical management guidelines for Niemann-Pick disease type C","volume":"13","author":"Geberhiwot","year":"2018","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.leukres.2026.108230_bib30","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1177\/0269216317690685","article-title":"Guidance on Conducting and REporting DElphi Studies (CREDES) in palliative care: Recommendations based on a methodological systematic review","volume":"31","author":"Junger","year":"2017","journal-title":"Palliat. Med"},{"key":"10.1016\/j.leukres.2026.108230_bib31","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.leukres.2026.108230_bib32","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41408-023-00946-z","article-title":"Real world data on outcomes of anti-CD38 antibody treated, including triple class refractory, patients with multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group (CMRG) Database","volume":"13","author":"Visram","year":"2023","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.leukres.2026.108230_bib33","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13206238","article-title":"Strengths and Weaknesses of Different Therapeutic Strategies for the Treatment of Patients with Multiple Myeloma Who Progress After the Frontline Use of Lenalidomide: A Narrative Review","volume":"13","author":"Mele","year":"2024","journal-title":"J. Clin. Med"},{"key":"10.1016\/j.leukres.2026.108230_bib34","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S1470-2045(21)00128-5","article-title":"Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial","volume":"22","author":"Dimopoulos","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.leukres.2026.108230_bib36","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00277-012-1445-y","article-title":"SIE, SIES, GITMO evidence-based guidelines on novel agents (thalidomide, bortezomib, and lenalidomide) in the treatment of multiple myeloma","volume":"91","author":"Barosi","year":"2012","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.leukres.2026.108230_bib37","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/s41571-025-01041-x","article-title":"EHA-EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma","volume":"22","author":"Dimopoulos","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.leukres.2026.108230_bib38","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41408-023-00804-y","article-title":"Clinical evidence for immune-based strategies in early-line multiple myeloma: current challenges in decision-making for subsequent therapy","volume":"13","author":"Raje","year":"2023","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.leukres.2026.108230_bib39","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/ejh.14161","article-title":"Real-world treatment patterns in patients initiating third-line therapy for relapsed or refractory multiple myeloma in Germany, Italy, the United Kingdom, France, and Spain","volume":"112","author":"Lehne","year":"2024","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.leukres.2026.108230_bib40","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41408-021-00432-4","article-title":"Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life","volume":"11","author":"Terpos","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.leukres.2026.108230_bib41","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13174320","article-title":"Choosing the Right Therapy for Patients with Relapsed\/Refractory Multiple Myeloma (RRMM) in Consideration of Patient-, Disease- and Treatment-Related Factors","volume":"13","author":"Gengenbach","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.leukres.2026.108230_bib42","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41408-023-00849-z","article-title":"Cardiac toxicities in multiple myeloma: an updated and a deeper look into the effect of different medications and novel therapies","volume":"13","author":"El-Cheikh","year":"2023","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.leukres.2026.108230_bib43","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1080\/03007995.2020.1816946","article-title":"Delphi, non-RAND modified Delphi, RAND\/UCLA appropriateness method and a novel group awareness and consensus methodology for consensus measurement: a systematic literature review","volume":"36","author":"Jandhyala","year":"2020","journal-title":"Curr. Med Res Opin."},{"key":"10.1016\/j.leukres.2026.108230_bib44","series-title":"Results from the randomized phase III DREAMM-7 study of belantamab mafodotin (belamaf)+ bortezomib, and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in relapsed\/refractory multiple myeloma (RRMM)","author":"Mateos","year":"2024"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212626000743?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212626000743?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:38:40Z","timestamp":1781051920000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212626000743"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":43,"alternative-id":["S0145212626000743"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2026.108230","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An Italian Delphi consensus on the current and future burden and clinical management of lenalidomide-refractory multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2026.108230","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108230"}}